ONCOLOGY Oncology is a core therapeutic area for PSI and as such brings a wide-ranging depth of expertise. PSI has been conducting trials in a variety of oncology indications, across all age groups and world geographies since 1994. Our commitment to thorough feasibility and “go-the-extra-mile “project management has secured PSI’s reputation for high quality and on-time delivery in the area of oncology.
þ90% of our Project Managers and 85% of our Clinical Operations staff have oncology experience. We have all the means to ensure that a team of experts will run your study. Our clients know that difficult studies are what PSI does best. With a staff turnover rate of <6%, this experience enables PSI to use not only historical data but informs our knowledge of current practices.
þ We give every project a thorough assessment through our dedicated, full-time Feasibility Department. With people located in 11 countries of North America, Europe, Asia and Latin America and led by our team of internal oncologists, medical doctors, laboratory experts, imaging specialists, logisticians, pharmacy and regulatory experts.
þIn recent years, our specialists have conducted hundreds of feasibility assessments for oncology studies in 50+ countries. These assessments cover, but are not restricted to, evaluation of the target population availability and factors that limit it, standards of care, competitive studies, regulatory climates and the need to engage particular Key Opinion Leaders into the study. We weigh all of these factors before making recommendations.
þThe upfront investment of time and medical expertise into each feasibility assessment underlies PSI’s patient enrollment success in oncology trials. For oncology studies, where competition for patients and complexity of design are leading characteristics, we apply our years of experience to determine the best sites and countries for each study.
For more information about PSI, please visit our website WWW.PSI-CRO.COM or reach us at CONTACT@PSI-CRO.COM
PSI deserves glowing recommendations! It’s a credit to all your employees for all their hard work and diligence and the pride they take in doing so. Director, Clinical Operations, USA
PSI has in-depth Phase II-IV experience in the following cancer types: Breast Cancer Gynecological Cancer Ovarian Cancer Endometrial Carcinoma Gastroenterology Colorectal Cancer Gastric Cancer Pancreatic Cancer Esophageal Cancer Hepatocellular Carcinoma Urology Bladder Cancer Prostate Cancer Renal Cell Carcinoma Pulmonary Non Small Cell Lung Cancer Small Cell Lung Cancer Melanoma Solid Tumors † †
Hematologic Malignancies Lymphomas Leukemias Multiple Myeloma Brain Cancers Glioblastoma Malignant Astrocytomas Head & Neck Cancer Supportive Care CINV † Chemo-induced Neutropenia Chemo-induced Neurotoxicity Chemo-induced Diarrhea Pain in Bone Metastases Radiation-induced Mucositis Oral Mucositis in Head & Neck Cancer Rare Cancers † Ewing family of Tumors or Rhabdomyosarcoma
Pediatric indications
WWW.PSI-CRO.COM PSI CRO AG Corporate Headquarters Baarerstrasse 113a, 6300 Zug, Switzerland • Tel: +41 41 228 10 00
Global Office Locations North America: Ft. Washington, PA / Burlingame, CA / San Francisco, CA Latin America: Buenos Aires, Argentina Europe: Oxford, UK / Munich, Germany / Neusiedl am See, Austria Minsk, Belarus / Sofia, Bulgaria / Prague, Czech Republic / Tallinn, Estonia Budapest, Hungary / Milan, Italy / Warsaw, Poland / Bucharest, Romania Belgrade, Serbia / Kiev, Ukraine / Russian Federation: St. Petersburg, Moscow, Novosibirsk
Operational Presence by Region North America / Europe / Latin America Asia-Pacific / South Africa